These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22768738)

  • 41. [The use of mildronat in heart failure in patients with chronic ischemic heart disease].
    Sakharchuk II; Denisenko GT; Grushko VS; Bodaretskaia OI; Pishchalenko AN
    Vrach Delo; 1989 Sep; (9):21-3. PubMed ID: 2609613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long-term vasodilator therapy for chronic congestive heart failure: is it effective?].
    Yasuda H; Obata H
    Kokyu To Junkan; 1985 Mar; 33(3):241-5. PubMed ID: 3892610
    [No Abstract]   [Full Text] [Related]  

  • 43. Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure.
    Nanda S; Martinez MW; Dey T
    J Am Coll Cardiol; 2010 Aug; 56(10):822; author reply 822. PubMed ID: 20797499
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical issues in the management of heart failure.
    Boccanelli A; Scardovi AB
    G Ital Cardiol; 1999 Oct; 29(10):1195-8. PubMed ID: 10546133
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of neurohormonal modulators in heart failure with relatively preserved systolic function.
    Rapp JA; Gheorghiade M
    Heart Fail Clin; 2005 Apr; 1(1):77-93. PubMed ID: 17386836
    [No Abstract]   [Full Text] [Related]  

  • 46. Myocardial lipid accumulation and lipotoxicity in heart failure.
    Schulze PC
    J Lipid Res; 2009 Nov; 50(11):2137-8. PubMed ID: 19687505
    [No Abstract]   [Full Text] [Related]  

  • 47. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Heart failure due to diastolic dysfunction: the treatment principles].
    Pinamonti B; di Lenarda A; Sinagra G
    Ital Heart J Suppl; 2000 Apr; 1(4):469-80. PubMed ID: 10832133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of amino acids in the modulation of cardiac metabolism during ischemia and heart failure.
    Marazzi G; Rosanio S; Caminiti G; Dioguardi FS; Mercuro G
    Curr Pharm Des; 2008; 14(25):2592-604. PubMed ID: 18991676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Erythrocyte functional activity in patients with heart failure and the possible means for its correction].
    Sakharchuk II; Sisetskiĭ AP; Artiukh VP; Starodub NF
    Ter Arkh; 1992; 64(9):88-90. PubMed ID: 1481164
    [No Abstract]   [Full Text] [Related]  

  • 51. The treatment of diastolic heart failure.
    Cody RJ
    Cardiol Clin; 2000 Aug; 18(3):589-96. PubMed ID: 10986591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heart failure: clinical aspects from basic research. Introduction.
    Regitz-Zagrosek V; Fleck E
    Eur Heart J; 1994 Dec; 15 Suppl D():1. PubMed ID: 7713096
    [No Abstract]   [Full Text] [Related]  

  • 53. [Metabolic treatment of ischemic cardiopathy].
    Morillas Blasco PJ; Hernándiz Martínez A; Pallarés Carratalá V; Portolés Sanz M; Cosín Aguilar J
    Rev Clin Esp; 2004 Feb; 204(2):109-18. PubMed ID: 15023313
    [No Abstract]   [Full Text] [Related]  

  • 54. [Electrical instability of the myocardium in patients with aortic stenosis].
    Samoĭlenko VV; Abdueva RA
    Kardiologiia; 2005; 45(11):94-7. PubMed ID: 16353071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Ischemic heart disease, heart failure, and their effects on cognitive function].
    Nagai M; Kario K
    Nihon Rinsho; 2014 Apr; 72(4):715-20. PubMed ID: 24796103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. γ-Butyrobetaine hydroxylase catalyses a Stevens type rearrangement.
    Henry L; Leung IK; Claridge TD; Schofield CJ
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4975-8. PubMed ID: 22765904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring and perioperative intervention in the postoperative patient with heart disease.
    Campbell DB; Waldhausen JA
    Surg Clin North Am; 1983 Oct; 63(5):1057-67. PubMed ID: 6227096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The patented uses of D-ribose in cardiovascular diseases.
    Shecterle LM; Terry KR; St Cyr JA
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):138-42. PubMed ID: 20236088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Letter to the editor: Is an ischemic etiology especially detrimental for women with heart failure?
    Berkvens CP; Mommersteeg PM
    Int J Cardiol; 2017 Feb; 229():142. PubMed ID: 27745909
    [No Abstract]   [Full Text] [Related]  

  • 60. Scratching beneath the surface: IL4Rα blockade and the progression from myocardial ischemic injury to heart failure.
    Wu DH; Senyo SE
    Am J Physiol Heart Circ Physiol; 2024 May; 326(5):H1177-H1179. PubMed ID: 38517226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.